Bank of New York Mellon’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Bank of New York Mellon’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-688	Closed	-$4.63K	–	4353
2023 Q4	$4.63K	Hold	688	–	–	﹤0.01%	4290
2023 Q3	$6.3K	Sell	688 -969	-58%	-$19.5K	﹤0.01%	4322
2023 Q2	$35K	Sell	1,657 -3,752	-69%	-$116K	﹤0.01%	4224
2023 Q1	$146K	Buy	5,409 +922	+21%	+$42.9K	﹤0.01%	4007
2022 Q4	$159K	Sell	4,487 -111	-2%	-$13.3K	﹤0.01%	4035
2022 Q3	$1.04M	Buy	4,598 +689	+18%	+$169K	﹤0.01%	3185
2022 Q2	$739K	Sell	3,909 -128	-3%	-$25.8K	﹤0.01%	3352
2022 Q1	$1M	Sell	4,037 -183	-4%	-$28.9K	﹤0.01%	3314
2021 Q4	$656K	Buy	4,220 +58	+1%	+$11.2K	﹤0.01%	3629
2021 Q3	$833K	Buy	4,162 +313	+8%	+$74.4K	﹤0.01%	3501
2021 Q2	$984K	Buy	3,849 +387	+11%	+$96.6K	﹤0.01%	3433
2021 Q1	$919K	Sell	3,462 -21	-0.6%	-$6.62K	﹤0.01%	3379
2020 Q4	$1.28M	Buy	3,483 +337	+11%	+$96.7K	﹤0.01%	3111
2020 Q3	$768K	Buy	3,146 +92	+3%	+$28.6K	﹤0.01%	3270
2020 Q2	$879K	Buy	3,054 +495	+19%	+$146K	﹤0.01%	3181
2020 Q1	$522K	Buy	2,559 +23	+0.9%	+$7.33K	﹤0.01%	3344
2019 Q4	$1.13M	Buy	2,536 +64	+3%	+$22.7K	﹤0.01%	3176
2019 Q3	$761K	Buy	2,472 +48	+2%	+$15.6K	﹤0.01%	3317
2019 Q2	$770K	Buy	2,424 +1,641	+210%	+$568K	﹤0.01%	3371
2019 Q1	$329K	Buy	783 +126	+19%	+$50.6K	﹤0.01%	3720
2018 Q4	$200K	Sell	657 -7	-1%	-$2.26K	﹤0.01%	3855
2018 Q3	$239K	Sell	664 -16	-2%	-$5.47K	﹤0.01%	3883
2018 Q2	$249K	Buy	680 +183	+37%	+$65.2K	﹤0.01%	3872
2018 Q1	$147K	Buy	497 +22	+5%	+$6.5K	﹤0.01%	3991
2017 Q4	$199K	Sell	475 -11	-2%	-$3.93K	﹤0.01%	3954
2017 Q3	$160K	Hold	486	–	–	﹤0.01%	3919
2017 Q2	$115K	Buy	486 +29	+6%	+$6.59K	﹤0.01%	3999
2017 Q1	$157K	Buy	457 +21	+5%	+$7.23K	﹤0.01%	3937
2016 Q4	$152K	Buy	436 +25	+6%	+$9.16K	﹤0.01%	3955
2016 Q3	$165K	Buy	411 +52	+14%	+$26.5K	﹤0.01%	3935
2016 Q2	$214K	Buy	+359	New	+$218K	﹤0.01%	3876
2016 Q1	–	Sell	-138	Closed	-$91K	–	4318
2015 Q4	$91K	Hold	138	–	–	﹤0.01%	4084
2015 Q3	$65K	Hold	138	–	–	﹤0.01%	4211
2015 Q2	$78K	Sell	138 -33	-19%	-$91.3K	﹤0.01%	4091
2015 Q1	$1.46M	Buy	171 +37	+28%	+$323K	﹤0.01%	3078
2014 Q4	$1.17M	Buy	134 +12	+10%	+$69.6K	﹤0.01%	3209
2014 Q3	$573K	Hold	122	–	–	﹤0.01%	3573
2014 Q2	$879K	Buy	122 +90	+281%	+$450K	﹤0.01%	3386
2014 Q1	$170K	Buy	+32	New	+$151K	﹤0.01%	3888

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

AWP

Accretive Wealth Partners Parsippany, New Jersey $412M AUM 15.82% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Bank of New York Mellon's EIGR Position: Q1 2024 in Review

Bank of New York Mellon sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 688 shares — an estimated $4.63K sold.

Bank of New York Mellon first reported a position in EIGR in Q1 2014 and held it in 39 quarters. The position peaked at $1.46M in Q1 2015. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

Bank of New York Mellon reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
Bank of New York Mellon sold 688 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $4.63K.
Bank of New York Mellon first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 39 quarters.
Bank of New York Mellon's Eiger BioPharmaceuticals, Inc. position peaked at $1.46M in Q1 2015.
24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Bank of New York Mellon's 13F filing for Q1 2024, filed 25 Apr 2024.